DOP2013000272A - Compuestos novedosos como inhibidores de diacilglicerol aciltransferasa - Google Patents

Compuestos novedosos como inhibidores de diacilglicerol aciltransferasa

Info

Publication number
DOP2013000272A
DOP2013000272A DO2013000272A DO2013000272A DOP2013000272A DO P2013000272 A DOP2013000272 A DO P2013000272A DO 2013000272 A DO2013000272 A DO 2013000272A DO 2013000272 A DO2013000272 A DO 2013000272A DO P2013000272 A DOP2013000272 A DO P2013000272A
Authority
DO
Dominican Republic
Prior art keywords
dgat
inhibitors
diacilglicerol
aciltransferasa
obesity
Prior art date
Application number
DO2013000272A
Other languages
English (en)
Spanish (es)
Inventor
Hemant Joshi
Donghui Qin
Mui Cheung
Raghuram Tangirala
Sridhar Reddy Bethi
Original Assignee
Glaxosmithkline Ip No 2 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip No 2 Ltd filed Critical Glaxosmithkline Ip No 2 Ltd
Publication of DOP2013000272A publication Critical patent/DOP2013000272A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Child & Adolescent Psychology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
DO2013000272A 2011-05-20 2013-11-20 Compuestos novedosos como inhibidores de diacilglicerol aciltransferasa DOP2013000272A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1452DE2011 2011-05-20
US201161503728P 2011-07-01 2011-07-01

Publications (1)

Publication Number Publication Date
DOP2013000272A true DOP2013000272A (es) 2014-05-15

Family

ID=47217645

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2013000272A DOP2013000272A (es) 2011-05-20 2013-11-20 Compuestos novedosos como inhibidores de diacilglicerol aciltransferasa

Country Status (34)

Country Link
US (4) US8859536B2 (enExample)
EP (1) EP2710013B1 (enExample)
JP (1) JP5844456B2 (enExample)
KR (1) KR101919080B1 (enExample)
CN (1) CN103703009B (enExample)
AU (1) AU2012259044B2 (enExample)
BR (1) BR112013029935B1 (enExample)
CA (1) CA2836669C (enExample)
CO (1) CO6811855A2 (enExample)
CR (1) CR20130602A (enExample)
CY (1) CY1118188T1 (enExample)
DK (1) DK2710013T3 (enExample)
DO (1) DOP2013000272A (enExample)
EA (1) EA023030B1 (enExample)
ES (1) ES2588748T3 (enExample)
HR (1) HRP20161089T1 (enExample)
HU (1) HUE028870T2 (enExample)
IL (1) IL229488A (enExample)
LT (1) LT2710013T (enExample)
MA (1) MA35185B1 (enExample)
ME (1) ME02479B (enExample)
MX (1) MX346494B (enExample)
MY (1) MY184553A (enExample)
PE (1) PE20141204A1 (enExample)
PH (1) PH12013502401A1 (enExample)
PL (1) PL2710013T3 (enExample)
PT (1) PT2710013T (enExample)
RS (1) RS55006B1 (enExample)
SG (1) SG195044A1 (enExample)
SI (1) SI2710013T1 (enExample)
SM (1) SMT201600328B (enExample)
UA (1) UA111360C2 (enExample)
WO (1) WO2012162129A1 (enExample)
ZA (1) ZA201308664B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101919080B1 (ko) 2011-05-20 2018-11-16 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 디아실글리세롤 아실트랜스퍼라제 억제제로서의 신규 화합물
EP3492474B1 (en) 2012-11-23 2021-08-11 GlaxoSmithKline LLC Intermediates used in the production of diacylglycerol acyltransferase inhibitors
WO2014081996A1 (en) * 2012-11-23 2014-05-30 Glaxosmithkline Llc Novel compounds as diacylglycerol acyltransferase inhibitors
US9796729B2 (en) 2012-11-23 2017-10-24 Glaxosmithkline Llc Compounds as diacylglycerol acyltransferase inhibitors
CN103524431B (zh) * 2013-09-24 2016-01-13 西安交通大学 3-苄基-4-喹唑啉酮类化合物及其合成方法和应用
WO2015049668A1 (en) 2013-10-03 2015-04-09 Glaxosmithkline Intellectual Property (No.2) Limited Novel compound as a diacylglycerol acyltransferase inhibitor
WO2015049667A1 (en) 2013-10-03 2015-04-09 Glaxosmithkline Intellectual Property (No.2) Limited Novel compound as a diacylglycerol acyltransferase inhibitor
CN103880757B (zh) * 2014-04-15 2016-02-24 上海毕得医药科技有限公司 一种5-羟基嘧啶-2-羧酸的合成方法
WO2016181409A1 (en) 2015-05-11 2016-11-17 Cadila Healthcare Limited Saroglitazar magnesium for the treatment of chylomicronemia syndrome -
WO2017064635A2 (en) 2015-10-14 2017-04-20 Cadila Healthcare Limited Pyrrole compound, compositions and process for preparation thereof
CN105732461A (zh) * 2016-02-03 2016-07-06 常州工程职业技术学院 5-甲氧基-6-卤代吲哚的制备方法
CN106083707B (zh) * 2016-06-01 2018-10-26 温州大学 一种非对称杂芳基硫醚的合成方法
CN107619932B (zh) * 2016-07-15 2020-08-07 中国科学院上海有机化学研究所 一种萃取组合物、萃取体系及其应用
CN107619928B (zh) * 2016-07-15 2020-08-07 中国科学院上海有机化学研究所 一种萃取组合物、萃取体系及其应用
RU2706655C1 (ru) * 2019-01-28 2019-11-19 Акционерное общество "Гознак" (АО "Гознак") Полимерсодержащее композиционное защищенное изделие
CN117603242B (zh) * 2023-11-30 2026-08-11 沧州普瑞东方科技有限公司 一种反式-1-乙氧乙烯基-2-硼酸频那醇酯的制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090036425A1 (en) * 2007-08-02 2009-02-05 Pfizer Inc Substituted bicyclolactam compounds
KR101685718B1 (ko) * 2008-12-19 2016-12-12 제넨테크, 인크. 헤테로시클릭 화합물 및 사용 방법
TW201038580A (en) * 2009-02-02 2010-11-01 Pfizer 4-amino-5-oxo-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-6(5H)-yl)phenyl derivatives
JP2012520887A (ja) * 2009-03-18 2012-09-10 シェーリング コーポレイション ジアシルグリセロールアシルトランスフェラーゼの阻害剤としての二環式化合物
ES2513915T3 (es) 2009-04-24 2014-10-27 F. Hoffmann-La Roche Ag Inhibidores de la tirosina quinasa de Bruton
KR101919080B1 (ko) 2011-05-20 2018-11-16 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 디아실글리세롤 아실트랜스퍼라제 억제제로서의 신규 화합물
US9796729B2 (en) 2012-11-23 2017-10-24 Glaxosmithkline Llc Compounds as diacylglycerol acyltransferase inhibitors

Also Published As

Publication number Publication date
CN103703009A (zh) 2014-04-02
AU2012259044B2 (en) 2015-09-17
US20160200736A1 (en) 2016-07-14
US9540400B2 (en) 2017-01-10
AU2012259044A1 (en) 2013-12-12
SG195044A1 (en) 2013-12-30
PT2710013T (pt) 2016-09-28
SI2710013T1 (sl) 2016-10-28
MX2013013566A (es) 2014-01-08
CO6811855A2 (es) 2013-12-16
KR20140045415A (ko) 2014-04-16
IL229488A (en) 2016-04-21
MA35185B1 (fr) 2014-06-02
UA111360C2 (uk) 2016-04-25
HUE028870T2 (en) 2017-01-30
US8859536B2 (en) 2014-10-14
BR112013029935A2 (pt) 2016-09-20
HRP20161089T1 (hr) 2016-10-21
NZ617991A (en) 2015-06-26
US9040517B2 (en) 2015-05-26
ES2588748T3 (es) 2016-11-04
CA2836669A1 (en) 2012-11-29
CA2836669C (en) 2019-03-19
HK1194738A1 (zh) 2014-10-24
IL229488A0 (en) 2014-01-30
ME02479B (me) 2017-02-20
EP2710013B1 (en) 2016-06-29
US9273069B2 (en) 2016-03-01
JP2014517839A (ja) 2014-07-24
SMT201600328B (it) 2016-11-10
EP2710013A1 (en) 2014-03-26
WO2012162129A1 (en) 2012-11-29
EA201391737A1 (ru) 2014-04-30
RS55006B1 (sr) 2016-11-30
KR101919080B1 (ko) 2018-11-16
LT2710013T (lt) 2016-09-12
PE20141204A1 (es) 2014-10-05
PH12013502401A1 (en) 2015-10-07
MX346494B (es) 2017-03-21
JP5844456B2 (ja) 2016-01-20
ZA201308664B (en) 2015-02-25
MY184553A (en) 2021-04-02
BR112013029935B1 (pt) 2020-12-15
CN103703009B (zh) 2016-08-17
DK2710013T3 (en) 2016-09-26
EA023030B1 (ru) 2016-04-29
PL2710013T3 (pl) 2017-08-31
EP2710013A4 (en) 2014-11-05
CY1118188T1 (el) 2017-06-28
US20150225425A1 (en) 2015-08-13
CR20130602A (es) 2014-08-13
US20140080809A1 (en) 2014-03-20
US20140378434A1 (en) 2014-12-25

Similar Documents

Publication Publication Date Title
MY184553A (en) Novel compounds as diacylglycerol acyltransferase inhibitors
UY32919A (es) Composición farmacéutica, forma de dosificación farmacéutica, procedimiento para su preparación, mé todos para su tratamiento y sus usos
ECSP13013068A (es) Halogenoalquil-1,3-oxazinas como inhibidores de la bace1 y/o bace2
MX2012013731A (es) Vacunas que comprenden colesterol y cpg como moleculas portadoras-adyuvantes unicas.
BR112012032579A2 (pt) "terapia de diabetes"
UA113165C2 (xx) Застосування комбінації баклофену і акампросату для лікування неврологічних захворювань та композиція, яка містить баклофен і акампросат
BR112014012230A2 (pt) fralda de vestir descartável de tamanho pequeno
IN2014MN02661A (enExample)
MX355267B (es) Análogos de carba-nucleósido 2´-sustituidos para tratamiento antivírico.
BR112016017193A2 (pt) Derivados de insulina, seus usos, e composição farmacêutica
MX2013012661A (es) Compuestos de piridazina biciclicos como inhibidores pim.
NZ724792A (en) Compounds and compositions as toll-like receptor 7 agonists
BR112012032721A2 (pt) compostos heterocíclicos, sua preparação e sua aplicação terapêutica
MX2018002223A (es) Derivados de insulina novedosos y usos medicos de los mismos.
DOP2013000273A (es) Compuestos novedosos como inhibidores de diacilglicerol aciltransferasa
IN2014DN03429A (enExample)
CL2010001577A1 (es) Uso de nifurtimox para preparar un medicamento util en el tratamiento de enfermedades causadas por giardias.
BR112015010196A2 (pt) métodos de tratar doença do fígado
IN2014CN04222A (enExample)
PE20150967A1 (es) Compuestos novedosos como inhibidores de diacilglicerol aciltransferasa
MX357828B (es) Composición con factores de crecimiento destinada al tratamiento intranasal de una enfermedad neurodegenerativa u otra patología del sistema nervioso central, y su método de fabricación.
WO2013068993A3 (en) Tyrosine isomers as therapeutic agents
EA201490935A1 (ru) Терапевтическая комбинация мемантина и баклофена и содержащая их фармацевтическая композиция
IN2013MU01154A (enExample)
IN2013MU01155A (enExample)